房颤患者队列中报告的卒中发生率存在巨大差异
该系统综述纳入34项未接受口服抗凝治疗的非瓣膜性房颤患者队列研究,发现总体卒中发生率高度异质(年率0.45%至9.28%),且CHA2DS2-VASc评分对应的卒中率在不同队列间差异显著,多数队列中评分1或2分的患者卒中率未达到抗凝净临床获益的预期阈值。
要点
- 房颤患者年卒中率在队列间差异巨大(0.45%-9.28%),与CHA2DS2-VASc评分不完全对应。
- CHA2DS2-VASc评分1分时,76%队列年卒中率<1%,仅18%>2%。
- 评分2分时,27%队列年卒中率<1%,40%在1%-2%,33%>2%。
核心结论
- 房颤患者总体卒中率及CHA2DS2-VASc评分对应的卒中率在队列间存在显著异质性,影响口服抗凝推荐阈值。
- 多数队列中CHA2DS2-VASc评分1或2分的患者卒中率未显示明确的抗凝净临床获益。
研究设计与样本
- 系统综述纳入34项未接受口服抗凝治疗的非瓣膜性房颤患者队列研究(包括队列研究和随机对照试验)。
主要发现
- 总体卒中率高度异质(Q=5706.54,P<0.001;I2=99.6%),年率范围0.45%至9.28%。
- 北美平均卒中率不足欧洲平均卒中率的三分之一(P<0.0001)。
- 随机效应回归显示研究间变异不能由队列地区、前瞻或回顾设计、研究日历年或结局事件聚类显著解释。
- CHA2DS2-VASc评分1分时,76%队列年缺血性卒中率<1%,仅18%>2%。
- CHA2DS2-VASc评分2分时,27%队列年卒中率<1%,40%在1%-2%,33%>2%。
关键数值与推荐
- CHA2DS2-VASc评分1分时,76%队列年缺血性卒中率<1%,18%>2%。
- CHA2DS2-VASc评分2分时,27%队列年卒中率<1%,40%在1%-2%,33%>2%。
- 抗凝净临床获益的年缺血性卒中阈值约为1%-2%。
临床怎么用
- 临床决策应考虑当地人群的实际卒中率,而非仅依赖CHA2DS2-VASc评分固定阈值。
- 对于CHA2DS2-VASc评分1或2分的房颤患者,抗凝净获益可能因人群而异,需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral anticoagulants decrease ischemic stroke rates in patients with atrial fibrillation (AF) but increase the risk of bleeding. For the average patient with AF, the threshold of annual ischemic stroke rate where the benefit of anticoagulation outweighs the bleeding risk (net clinical benefit) has been shown to be ≈1% to 2%. Guideline recommendations for oral anticoagulants in AF are based on the CHA2DS2-VASc stroke risk point scores, assuming that those scores translate to fixed stroke rates. However, the relationship between stroke point scores and annual stroke rates may vary substantially across populations. We sought to comprehensively assess the reported rates of stroke in patients with AF and the relationship of stroke rates to stroke risk point scores. METHODS: A systematic review of cohort studies and randomized controlled trials enrolled patients with nonvalvular AF not treated with oral anticoagulants. RESULTS: Of the 3552 studies screened, we identified 34 studies eligible for analysis. Overall stroke rates in cohort studies were highly heterogeneous (Q=5706.54, P<0.001; I2 = 99.6%) and ranged from 0.45% to 9.28% per year, despite being of similar objective study quality. The mean North American stroke rate was less than one-third that of the mean European stroke rate (P<0.0001). However, a random effects regression indicated that between-study variability was not significantly accounted for by cohort region, prospective versus retrospective design, calendar year of study, or outcome event cluster. At a CHA2DS2-VASc score of 1, 76% of cohorts reported ischemic stroke rates <1% per year and only 18% of cohorts reported a stroke rate >2% per year. At a CHA2DS2-VASc score of 2, 27% of cohorts reported stroke rates below 1% per year, 40% reported stroke rates between 1 and 2% per year, and 33% reported stroke rates >2% per year. CONCLUSIONS: Substantial variation exists across cohorts in overall stroke rates and rates corresponding to CHA2DS2-VASc point scores. These variations can affect the point score threshold for recommending oral anticoagulants in AF. The majority of cohorts did not observe stroke rates that would indicate a clear expected net clinical benefit for anticoagulating AF patients with CHA2DS2-VASc scores of 1 or 2.
引用
- Quinn GR, Severdija ON, Chang Y, et al. Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. Circulation. 2016. PMID: 27799272. doi:10.1161/CIRCULATIONAHA.116.024057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。